Review of advances in FOLFOX-HAIC for conversion, neoadjuvant, and adjuvant therapy in hepatocellular carcinoma

Abstract

FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil)-based hepatic arterial infusion chemotherapy (FOLFOX-HAIC) has emerged as a promising locoregional strategy in the multimodal management of hepatocellular carcinoma (HCC), particularly for patients with intermediate or advanced-stage disease. This narrative review summarizes recent clinical evidence on the application of FOLFOX-HAIC across the therapeutic continuum: in conversion, neoadjuvant, and adjuvant settings. We conducted an analysis based on a search of PubMed, Embase, China National Knowledge Infrastructure (CNKI) and conference abstracts, which incorporated phase II/III trials, retrospective cohort studies, multicenter real-world studies, and meta-analyses. Evidence indicates that FOLFOX-HAIC, especially when combined with targeted therapy and immunotherapy, yields superior objective response rates and higher rates of conversion to curative resection compared to conventional transarterial chemoembolization (TACE). Furthermore, as postoperative adjuvant therapy, it significantly reduces recurrence risk and prolongs survival in high-risk patients, such as those with microvascular invasion. In the neoadjuvant setting, these combinations can induce profound pathological responses, potentially improving outcomes for resectable patients at high risk of recurrence. Consequently, FOLFOX-HAIC represents an evolving cornerstone of HCC therapy. However, current evidence is largely derived from retrospective and small prospective studies, underscoring the urgent need for large-scale phase III randomized controlled trials to standardize regimens, optimize patient selection, and confirm long-term survival benefits.

Keywords

Hepatocellular carcinoma / FOLFOX-HAIC / conversion therapy / neoadjuvant therapy / adjuvant therapy

References

[1] El-Serag HB.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology2007;132:2557-76 PMCID:12599654

[2] Saito A,Kobayashi M.Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning.Mod Pathol2021;34:417-25 PMCID:PMC7817520

[3] Singh SP,Chand P.Global epidemiology of hepatocellular carcinoma.J Clin Exp Hepatol2025;15:102446 PMCID:PMC11626783

[4] Chen S,Yu W,He C.Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: a multicenter retrospective study.J Gastrointest Surg2022;26:2292-300

[5] Pan Y,Wang J.Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.J Cancer Res Clin Oncol2023;149:14761-74 PMCID:PMC11797165

[6] Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. PMCID:2335261

[7] Zhang W,Liu C.Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.Front Immunol2023;14:1127349 PMCID:PMC10169627

[8] Tanaka T.Transarterial chemoembolization for hepatocellular carcinoma: current role and techniques.Interv Radiol2025;10:e20240016 PMCID:PMC12078018

[9] Li QJ,Chen HW.Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial.J Clin Oncol2022;40:150-60

[10] He M,Zou R.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial.JAMA Oncol2019;5:953-60 PMCID:PMC6512278

[11] Zhou H.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.Biosci Trends2021;15:155-60

[12] Wang J,Wu T.Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study.J Hepatocell Carcinoma2022;9:999-1010 PMCID:9483136

[13] Zhu C,Liu D.Oxaliplatin-induced hepatic sinusoidal obstruction syndrome.Toxicology2021;460:152882

[14] Zheng K,Fu S.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial.Radiology2022;303:455-64

[15] Yang M,Liu H.Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis.Front Pharmacol2024;15:1410767 PMCID:PMC11322119

[16] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:7523244

[17] Li H,Zhang X.Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm phase II study.JCO2025;43:e16212

[18] Zhao M,Zhong S.983P Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) - the DurHope study.Ann Oncol2023;34:S608

[19] Liu D,Liu C.Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.Neoplasma2023;70:811-8

[20] Xin Y,Yang H.Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.Front Immunol2022;13:929141 PMCID:PMC9388744

[21] Pan L,He Q.Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: a prospective, single-arm phase II trial.J Clin Oncol2024;42:4103

[22] Zhao Z,Wen S.Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis.Front Pharmacol2024;15:1499269 PMCID:PMC11747745

[23] Liu G,He Q.Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.J Hepatocell Carcinoma2024;11:1415-28 PMCID:11264130

[24] Chen S,Wu Z.Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study.J Hepatocell Carcinoma2023;10:1209-22 PMCID:10390715

[25] Lai Z,Bu X.Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial.Eur J Cancer2022;174:68-77

[26] Luo L,Zhu G.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience.Front Oncol2022;12:1004652 PMCID:PMC9552711

[27] Zhang N,Yu B.Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma.Innovation2025;6:100910 PMCID:PMC12277749

[28] Lin ZP,Chen D.Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.World J Gastroenterol2024;30:2321-31 PMCID:11130568

[29] Li R,Li H.Hepatic arterial infusion chemotherapy combined lenvatinib and PD-1 inhibitor showed improved survival for infiltrative hepatocellular carcinoma: a multicenter cohort study.J Hepatocell Carcinoma2024;11:1727-40 PMCID:11397264

[30] Yang Y, Sun J, Cai J, et al.; Chinese Association of Liver Cancer and Chinese Medical Doctor Association. Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 Edition). Liver Cancer. 2025;14:311-33. PMCID:PMC12180802

[31] Zhang W,Gao W.Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.Front Immunol2025;16:1596864 PMCID:12171213

[32] Nevola R,Criscuolo L.Predictors of early and late hepatocellular carcinoma recurrence.World J Gastroenterol2023;29:1243-60 PMCID:10011963

[33] Chi QY,Wang SJ.Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study.BMC Cancer2025;25:1162 PMCID:12247254

[34] Liu Y,Guo X.Comparative effectiveness of adjuvant treatment for resected hepatocellular carcinoma: a systematic review and network meta-analysis.Front Oncol2021;11:709278 PMCID:8445365

[35] Hu L,Lin J,Wang A.Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis.World J Surg Oncol2023;21:121 PMCID:10069128

[36] Li SH,Cheng Y.Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study.J Clin Oncol2023;41:1898-908 PMCID:10082249

[37] Wen Y,Mei J.Hepatic arterial infusion chemotherapy vs transcatheter arterial chemoembolization as adjuvant therapy following surgery for MVI-positive hepatocellular carcinoma: a multicenter propensity score matching analysis.J Hepatocell Carcinoma2024;11:665-78 PMCID:11001557

[38] Long Y,He X.Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: a multicenter, prospective, single-arm, phase II trial.J Clin Oncol2024;42:e16227

[39] Liang Y,Shang J.Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis.BMC Cancer2025;25:418 PMCID:11887270

[40] Yang J,Chen Y,Deng Y.Adjuvant ICIs plus targeted therapies reduce HCC recurrence after hepatectomy in patients with high risk of recurrence.Curr Oncol2023;30:1708-19 PMCID:9955678

[41] Ouyang J,Zhou Y.Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study.Hepatobiliary Surg Nutr2024;13:616-31 PMCID:11336524

[42] Singal AG,Yopp A,Pinato DJ.Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future.Hepatol Commun2024;8:e0430 PMCID:11150030

[43] Hu Z,Pan Y.Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma.Front Pharmacol2023;14:1210835 PMCID:10338864

[44] Pan Y,Chen J.Comparison between portal vein perfusion chemotherapy and neoadjuvant hepatic arterial infusion chemotherapy for resectable intermediate to advanced stage hepatocellular carcinoma.Ann Surg Oncol2022;29:2016-29

[45] Shi Y,Li X.Prognosis of neoadjuvant HAIC and lenvatinib followed by surgery versus direct resection for resectable or borderline resectable hepatocellular carcinoma: a real-world study.J Hepatocell Carcinoma2024;11:2063-76 PMCID:11514688

[46] Tao P, Wei Y, Zhu G, et al. 187P Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero). Ann Oncol 2023;34:S1547-8. Available from: https://www.annalsofoncology.org/article/S0923. [Last accessed on 24 Apr 2026].

[47] Wu X,Wang S.Neoadjuvant targeted immunotherapy followed by surgical resection versus upfront surgery for hepatocellular carcinoma with macrovascular invasion: a multicenter study.J Cancer2024;15:3024-33 PMCID:11064256

[48] Yuan Y,Yang Z.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.Int J Surg2023;109:1222-30 PMCID:10389515

[49] Zhao W,Wu Y.Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.Transl Cancer Res2024;13:2315-31 PMCID:11170507

[50] Wu C,Li X.TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden - a propensity-score matching comparative study.Front Immunol2025;16:1664756 PMCID:PMC12682802

[51] Yang J,Li J.Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.J Gastrointest Oncol2024;15:346-55 PMCID:10932649

[52] Abza GB,Annaert P.Inhibition of ABC transporters by sorafenib and lenvatinib: implications for drug-induced cholestasis.Xenobiotica2025;55:99-109

[53] Hountondji L,Lebossé F.Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.JHEP Rep2023;5:100719 PMCID:10149360

[54] Tang HH,Zhang ZC.Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies.BMC Cancer2025;25:603 PMCID:11966872

[55] Lv X,Zhang EL.Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: a comprehensive review.World J Surg Oncol2025;23:166 PMCID:12034129

[56] Zhao Y,Liu S.Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score.J Cancer Res Clin Oncol2023;149:5181-92 PMCID:10349720

[57] Zhu AX,Yen CJ.Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma.Clin Cancer Res2022;28:3537-45 PMCID:9662926

[58] Li J,Teng Z,Li D.Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.Front Immunol2024;15:1430196 PMCID:11442238

[59] Lewandowski RJ,Abouchaleh N.Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology2018;287:1050-8